Latest news with #DeepHealth
Yahoo
19 hours ago
- Business
- Yahoo
DeepHealth, a RadNet Subsidiary, Receives FDA Clearance for Remote Scanning Solution, TechLive™
TechLive™ is a vendor-agnostic integrated solution enabling remote scanning of MR, CT, PET/CT, and Ultrasound procedures Amidst radiology technologist shortages, remote scanning in a command center configuration enables the workforce to scan at multiple locations simultaneously with a high level of expertise RadNet has connected more than 300 MR, CT, PET/CT, and Ultrasound systems with TechLive™, delivering operational efficiency and increased access to advanced procedures LOS ANGELES and SOMERVILLE, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and global leader in AI-powered health informatics, announced today that it has received FDA 510(k) clearance for TechLive™ - a remote scanning solution enabling centralized operation and supervision of MR, CT, PET/CT, and Ultrasound procedures. Amidst tech labor shortages and inflationary wage pressure, TechLive™ empowers technologists to scan for multiple locations, enables improved operational efficiency, extends center operating hours, and enhances access to complex procedures. More than 300 of RadNet's MR, CT, PET/CT, and Ultrasound systems are now connected with DeepHealth's TechLive™ solution, resulting in increased patient throughput and improved quality through remotely matching expert staff with complex modalities in real-time. Over the past decade, radiology workloads have steadily increased, while the number of qualified technologists have not grown proportionally. In a pilot deployment at 64 locations inside of RadNet's New York area facilities, TechLive™ significantly contributed to a 42% decrease in MRI room closure hours during the second quarter of 2025 as compared with the same period in 2024, allowing more patients to receive timely scans. Additionally, as a result of the remote expert involvement during the same pilot deployment, TechLive™ contributed to an increase in complex procedures. Furthermore, in extending remote scanning capabilities to Ultrasound, TechLive™ is enabling experienced senior sonographers and physicians to remotely guide technologists on-site through complex cases in a modality that is heavily dependent upon real-time, operator expertise. "TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries." About DeepHealthDeepHealth is a wholly-owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for all companies within RadNet's Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging. Building on the strengths of the companies it has integrated and is rebranding (e.g., eRAD Radiology Information and Image Management Systems and Picture Archiving and Communication System, Aidence lung AI, DeepHealth, Kheiron, and iCAD breast AI, Quantib prostate and brain AI, and See-Mode thyroid and breast AI), DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in lung, breast, prostate, and brain health. At the heart of DeepHealth's portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum. Thousands of radiologists at hundreds of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable, and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. About RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit DeepHealth ContactAndra AxenteDirector of Communications+ RadNet, Inc. ContactMark StolperExecutive Vice President and Chief Financial Officer310-445-2800 Forward-Looking Statements This communication contains certain 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'intend,' 'may,' 'outlook,' 'plan,' 'potential,' 'possible,' 'predict,' 'project,' 'seek, 'should,' 'target,' 'will' or 'would,' the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding the streamlining of delivery and deployment across healthcare facilities, and TechLive creating a foundation for more efficient, financially sustainable and high-quality patient care across the broadest set of imaging modalities, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet's control. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of RadNet's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's control. RadNet's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet nor its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet's business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the Securities and Exchange Commission (the 'SEC'), including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC. Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.
Techday NZ
3 days ago
- Business
- Techday NZ
DeepHealth gains FDA approval for remote scanning in ultrasound
DeepHealth has received FDA 510(k) clearance for its TechLive remote scanning solution, enabling centralised operations and supervision for MR, CT, PET/CT and, for the first time, Ultrasound procedures. Addressing staffing challenges The company's announcement comes as radiology workloads continue to rise, with the number of qualified technologists failing to keep pace. This disparity has contributed to staffing gaps and periods of MRI room closures, limiting access to complex scans and procedures for patients. DeepHealth aims to address these issues by equipping technologists with the ability to operate scanning equipment for multiple locations remotely. This model enables improved operational efficiency and extends the scope of experienced staff to more cases across different centres. Results from pilot study During a pilot deployment at 64 RadNet sites in the New York area, DeepHealth's TechLive solution contributed to a 42 percent decrease in MRI room closure hours during the second quarter of 2025, compared with the same period in 2024. According to DeepHealth, this resulted in more timely scans for patients and improved access to complex procedures. The company has also reported that, through remote expert involvement, TechLive contributed to an increase in the number of complex imaging procedures performed at these locations. The TechLive system currently connects over 300 RadNet MR, CT, PET/CT, and Ultrasound systems. By implementing real-time remote expertise, experienced senior sonographers and physicians can now guide on-site technologists through complex ultrasound cases - a modality noted for its reliance on operator skill and immediate decision-making. Company perspectives "TechLive represents a paradigm shift in how we approach imaging operations. By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. Operational impact TechLive has been introduced to streamline imaging operations, with specific attention to enhancing operational efficiency, extending operating hours for centres, and improving access to more complex diagnostic and therapeutic procedures. The solution's extension to Ultrasound marks the first industry application of remote scanning and supervision for this modality. By matching expert staff to complex cases in real time, DeepHealth seeks to increase patient throughput and maintain quality standards, while also helping care providers manage ongoing labour shortages and wage pressures in health services. Sector implications The increasing adoption of remote scanning solutions comes as healthcare providers face higher demand for complex imaging and persistent difficulty in recruiting qualified technologists. As radiology services evolve, solutions like TechLive are being considered as part of long-term strategies to maintain patient access and support a sustainable operational model. Follow us on: Share on:
Yahoo
16-07-2025
- Business
- Yahoo
Hologic Rides on AI-Powered Breast Health Innovations: What's Next?
Breast cancer continues to be a significant global health challenge and the leading cause of cancer-related deaths among women. Artificial Intelligence is playing an increasingly vital role in addressing this issue, which involves managing clinical data, identifying ambiguous cases, forecasting patient outcomes and enabling more informed clinical decisions. U.S. medical device maker Hologic HOLX has long been at the forefront of using AI to enhance accuracy and efficiency for radiologists. In 2009, the company set a new standard in breast cancer screening with the launch of its Genius 3D mammography exam — the only FDA-approved mammogram clinically proven to be superior to 2D mammography for all women, including those with dense breast tissue. While Hologic is navigating a softer year in capital equipment sales, it continues to hold a leading share of the U.S. mammography market. At the core of the company's breast health offerings is its Genius AI platform, designed to enhance cancer detection, operational efficiency and support clinical decisions. The platform also powers the 3DQuorum technology, approved by the FDA in 2019, which delivers meaningful productivity gains for radiologists due to a significant reduction in read time. Despite widespread adoption of AI tools in breast cancer screening, many algorithms have exhibited racial disparities across applications. Hologic's Genius AI Detection 2.0 solution stands out, with research confirming consistent results across diverse populations. Building on this, the company is set to launch its Genius AI Detection PRO solution in the United States, promising even greater accuracy and fewer false positives. The next-generation solution was recently named 'Best New Imaging Technology Solution' by MedTech Breakthrough, reinforcing Hologic's leadership in breast imaging AI. Furthermore, HOLX is preparing for the commercial launch of the Envision Mammography Platform, which provides a high-speed 3D mammogram with a 2.5-second scan time — the fastest in the market. GE Healthcare GEHC boasts the largest global footprint of breast imaging systems, with a portfolio that includes 2D and 3D Mammography, Ultrasound, Automated Breast Ultrasound (ABUS), MRI, CT and PET/CT. GEHC's recent innovations include the Pristina Via mammography system, which enhances the screening experience for both technologists and patients, and the Invenia ABUS Premium — a 3D ultrasound with advanced AI and features to drive faster, reproducible supplemental screening and simplify exam readings on patients with dense breasts. RadNet RDNT, via its subsidiary DeepHealth, recently acquired See-Mode Technologies PTE LTD. The acquisition adds AI-powered ultrasound detection, characterization and reporting solutions for thyroid and breast to DeepHealth's population health solutions. Furthermore, in April 2025, RadNet announced that it would acquire iCAD, known for its clinically proven AI-powered breast health solutions, in an all-stock transaction. iCAD will also be integrated into the DeepHealth portfolio of solutions. Year to date, Hologic shares have declined 12.3% compared with the industry's 10.2% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 14.25X, discounted than the industry average of 28.35X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for EPS have dropped 0.5% for fiscal 2025 and 1.1% for 2026 over the past 60 days. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report RadNet, Inc. (RDNT) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Techday NZ
05-06-2025
- Health
- Techday NZ
DeepHealth boosts ultrasound AI by integrating See-Mode team
DeepHealth will incorporate See-Mode Technologies' expertise and AI technologies for thyroid and breast ultrasound into its population health solutions following RadNet's acquisition of See-Mode Technologies. See-Mode's commercially available AI-powered ultrasound detection, characterisation, and reporting solutions for thyroid and breast will be added to DeepHealth's suite of services. These technologies automatically detect and characterise thyroid nodules and breast lesions during ultrasound imaging, aiming to improve diagnostic accuracy and streamline clinical workflows through the generation of standardised reports. The integration is set against the backdrop of rising global rates of thyroid cancer, which is among the fastest-growing cancer diagnoses worldwide. Alongside breast cancer, it remains a prevalent pathology, particularly impacting women. Real-world deployment of See-Mode's FDA-cleared thyroid ultrasound AI at selected RadNet imaging centres has already shown operational benefits, with workflow efficiency improvements and enhancements to diagnostic accuracy. The company reported that the inclusion of See-Mode's automated detection and reporting has resulted in up to a 30 per cent reduction in scan time in the centres where it has been piloted. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, "Thyroid cancer is one of the fastest growing cancer diagnoses worldwide and, alongside breast cancer, is among the most common cancers affecting women. In the US alone, approximately 20 million ultrasound exams are performed annually for thyroid and breast combined. With ultrasound imaging inherently complex and user and radiologist-dependent, the opportunity to improve care through AI is significant." Dr. Berger further noted, "Early deployment of See-Mode's FDA-approved thyroid ultrasound AI across a portion of our imaging centers has demonstrated up to a 30% reduction in scan time as a result of increased workflow efficiency from See-Mode's automated detection and reporting. With demand exceeding available appointment slots for many of our over 900 ultrasound units, the increase in capacity created by See-Mode's technology should improve our ability to drive better access and more revenue through RadNet's existing centers. Furthermore, there is already a reimbursement code that makes a portion of our approximately 250,000 annual thyroid ultrasounds eligible for additional reimbursement. We aim to expand these efficiencies to breast screening and other clinical areas in our more than two million annual ultrasound studies. These opportunities will also be sold and marketed by DeepHealth to third parties as we further commercialize the offerings." See-Mode's AI technologies are currently cleared for commercial distribution in the United States, Canada, Australia, New Zealand, and Singapore. The acquisition supports DeepHealth's stated objective to strengthen its portfolio of AI-driven population health solutions and to address clinical and operational challenges in high-volume care settings. Dr. Milad Mohammadzadeh, Co-Founder of See-Mode, added: "Ultrasound is complex, time-consuming, and high-volume—exactly where AI can make a difference. By joining RadNet and DeepHealth's combined access to real-world clinical data and expertise at an unprecedented scale, we have an extraordinary platform to build the future of ultrasound." Echoing these remarks, Kees Wesdorp, President and Chief Executive Officer of RadNet's Digital Health division, said: "We are excited to integrate See-Mode's technology in thyroid and breast ultrasound into DeepHealth's comprehensive portfolio of AI-powered solutions for breast, lung, prostate, and brain, to address clinical and operational challenges in high-volume care settings. The technology and the team's expertise will be the basis for future AI-powered ultrasound solutions that will add to the growth engine of DeepHealth." According to the information provided, DeepHealth currently operates more than 900 ultrasound units, conducting over two million ultrasound examinations each year. The company expects that the integration of See-Mode's technology will allow it to manage greater demand, improve workflow efficiencies, and address current appointment slot limitations. Industry sources cited in the release note that in the United States alone, approximately 20 million ultrasound exams are performed each year for thyroid and breast combined. RadNet and DeepHealth aim to capitalise on these volumes by promoting their expanded suite of AI-driven solutions to both internal and third-party customers. See-Mode's team and technology base in Singapore and Australia will join the DeepHealth operations, contributing their expertise to ongoing and future development of AI-driven ultrasound solutions. This collaboration is expected to facilitate the development of new applications in high-volume diagnostic imaging and to support improved access and outcomes across RadNet's network of imaging centres.
Yahoo
21-05-2025
- Business
- Yahoo
SHINE Announces Two Strategic Appointments to Advance Fusion Technology and Market Expansion
Healthcare technology leader Dr. Gregory Sorensen joins Board of Directors; Defense expert Col. (Ret.) Gregory Van Dyk joins as Strategic Advisor JANESVILLE, Wis., May 21, 2025 /PRNewswire/ -- SHINE Technologies, LLC, a next-generation fusion technology company with commercialized platforms in industrial testing and medical isotopes, today announced the appointments of Dr. Gregory Sorensen, co-founder of DeepHealth and Chief Science Officer of RadNet, and Col. (Ret.) Gregory K. Van Dyk, U.S. Air Force, as strategic advisor to its Board of Directors. These appointments bring deep expertise in healthcare technology and national security to SHINE as the company expands the reach of its fusion applications across commercial and defense markets. "Fusion technology provides real-world solutions to big infrastructure problems in highly specialized markets," said Greg Piefer, founder and CEO of SHINE. "These appointments expand our ability to understand and access these markets quickly. Dr. Sorensen is a strong addition to our already distinguished board, having rare depth in the healthcare space that spans founding, growing, and selling startups through executive operations at multinational conglomerates. Col. Van Dyk brings a career of leadership and widespread connectivity in the radiation effects testing arena, with a specific focus on the effects of DT fusion neutrons." Dr. Sorensen: Guiding Commercial Strategy and Innovation Dr. Sorensen brings decades of experience at the intersection of healthcare, imaging, and technology. As co-founder of DeepHealth (now RadNet's AI division) and former President and CEO of Siemens Healthcare North America, he has led the development and commercialization of transformative medical technologies. He will advise SHINE on strategic growth initiatives, partnerships, and the expansion of its fusion-enabled medical isotope business. "SHINE represents the promise of fusion – not as a science experiment, but as a real-world solution," said Dr. Sorensen. "I'm excited and honored to help guide the company's growth into new healthcare and commercial markets." Col. (Ret.) Van Dyk: Advancing National Security through Fusion Col. (Ret.) Van Dyk, Ph.D. joins SHINE following a distinguished 22-year career in the U.S. Air Force, where he specialized in nuclear engineering, fusion technology, and strategic deterrence. He previously led the Department of Defense's Fusion for National Security initiative and managed a $207 million annual R&D portfolio at the National Nuclear Security Administration along with leading two multi-billion-dollar programs in the Department of Defense. His appointment comes at a critical time as SHINE expands FLARE (Fusion Linear Accelerator for Radiation Effects), a high-energy neutron testing service that enables defense contractors to evaluate the resilience of microelectronics and mission-critical systems in extreme radiation environments. "SHINE's fusion platform is practical, innovative, and timely," said Van Dyk. "FLARE offers a new capability for understanding how our most important defense technologies perform under the toughest conditions." About SHINE Headquartered in Janesville, Wisconsin, SHINE is an industry leader in next-generation fusion, developing innovative fusion-based technology that combines safety, cost-efficiency and environmental responsibility. SHINE has successfully commercialized fusion across multiple applications, including neutron testing markets such as neutron radiography, radiation-effects testing and fusion material research. It has commercialized and is scaling its proprietary medical isotope production, processes, supplying high-quality radioisotopes essential for procedures including diagnosing heart disease and cancer as well as cancer therapy. Beyond these applications, SHINE is pioneering nuclear waste recycling to make nuclear energy more sustainable. Its long-term purpose is to change the way humans make energy by commercializing fusion energy. Unlike other fusion companies, SHINE takes a commercially driven path mirroring successful deep-tech industries. Through this visionary approach, SHINE is advancing technology, healthcare, and sustainable energy, making a lasting impact across multiple sectors. View original content to download multimedia: SOURCE SHINE Technologies, LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
